Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in prostate cancer
- Trial result Spotlight
Prostate cancer
Apalutamide (androgen receptor inhibitor) + perioperative ADT improves 5-year MFS in high-risk localized/locally advanced prostate cancer undergoing prostatectomy
Apalutamide is an oral androgen receptor pathway inhibitor added to standard androgen-deprivation therapy (ADT) to intensify perioperative systemic control around radical prostatectomy. In the Phase 3 double-blind…
NCT03767244 - Trial result Spotlight
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR inhibitor) boosts 3-year PFS to 77% in HRR-altered mHSPC
Talazoparib is an oral PARP1/2 inhibitor combined with enzalutamide, a potent androgen-receptor signaling inhibitor, on top of ADT in TALAPRO-3 (Phase 3, double-blind; NCT04821622) for metastatic androgen pathway…
NCT04821622 - Trial result Spotlight
Prostate cancer
ABBV-969 (PSMA/STEAP1 dual-targeting Top1i ADC) drives 45% ORR and 67% PSA50 in heavily pretreated mCRPC
ABBV-969 is a first-in-class dual-targeting antibody–drug conjugate (ADC) against PSMA and STEAP1 delivering a topoisomerase-1 inhibitor payload, evaluated as Q3W monotherapy in the Phase 1 FIH dose-escalation study…
NCT06318273 - Trial result
Prostate cancer
COMPPARE Proton Therapy vs IMRT (photon) Shows No 2-Year Bowel QOL Advantage in Localized Prostate Cancer
COMPPARE (NCT03561220) is a large prospective, non-randomized comparative effectiveness study testing proton therapy (PT; particle RT with Bragg-peak dose deposition) versus photon IMRT in treatment-naïve localized…
NCT03561220 - Trial result
Prostate cancer
Apalutamide (AR antagonist) + ADT periop boosts pCR/MRD and improves 5-year MFS after prostatectomy in high-risk localized/locally advanced disease
Apalutamide (APA), an androgen receptor inhibitor, was added to androgen deprivation therapy (ADT) perioperatively (6 months neoadjuvant, then 6 months adjuvant) around radical prostatectomy (RP) in the double-blind…
NCT03767244 - Trial result
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR inhibitor) halves rPFS risk in HRR-altered mCSPC
Talazoparib is an oral PARP inhibitor that exploits homologous recombination repair (HRR) deficiency, and enzalutamide is an androgen-receptor signaling inhibitor; in the double-blind Phase 3 TALAPRO-3 trial…
NCT04821622 - Trial result
Prostate cancer
MMAI digital pathology AI biomarker predicts abiraterone benefit (CYP17 inhibition) in very high-risk M0 prostate cancer
MMAI is a locked multimodal AI model built from digital pathology plus PSA, T-stage, and age, tested post hoc across two sequential randomized STAMPEDE Phase 3 abiraterone comparisons in clinically very high-risk,…
NCT00268476 - Trial result
Prostate cancer
Enzalutamide + ribociclib (CDK4/6) misses PSA50 bar but extends rPFS/OS in RB+ mCRPC
Enzalutamide is an androgen receptor (AR) inhibitor and ribociclib is an oral CDK4/6 inhibitor intended to “re-awaken” RB tumor suppressor function by preventing RB hyperphosphorylation; RiboX (Phase Ib/II;…
NCT02555189 - Trial result
Prostate cancer
Enzalutamide-era mCRPC: ctDNA AR enhancer/AR copy gains sharpen rPFS risk stratification (Alliance A031201)
A031201 randomized chemotherapy-naïve mCRPC patients to the androgen receptor (AR) pathway inhibitor enzalutamide ± abiraterone acetate/prednisone (n=776 with baseline ctDNA profiled by the AR-ctDETECT assay;…
NCT01949337 - Trial result
Prostate cancer
ST-DoxPCa (AI “virtual spatial transcriptomics”) identifies an OS-benefiting subgroup for adjuvant docetaxel in high-risk localized prostate cancer
ST-DoxPCa is an AI/computational pathology biomarker built from routine H&E biopsies using a Vision Transformer to infer spot-level expression for a prostate gene panel (distilled to a locked 26-gene signature;…
- Trial result
Prostate cancer
Rucaparib (PARP inhibitor) extends rPFS in BRCA-mutant mCRPC regardless of when prior ARPI was used
Rucaparib is an oral PARP inhibitor evaluated in the Phase 3 TRITON3 trial (NCT02975934) versus physician’s choice of docetaxel or an ARPI (abiraterone/enzalutamide) in BRCA1/2-mutated mCRPC after progression on 1…
NCT02975934 - Trial result
Prostate cancer
Xaluritamig (STEAP1×CD3 T-cell engager) + abiraterone posts 58% PSA50 and 43% ORR in chemo‑naïve mCRPC
Xaluritamig (xalu) is a STEAP1×CD3 bispecific T-cell engager combined with abiraterone acetate + predniso(lo)ne in an open-label Phase 1 dose exploration/expansion study (NCT04221542) in taxane-naïve mCRPC with ≤2…
NCT04221542 - Trial result
Prostate cancer
Cabazitaxel/carbo + nivolumab/ipilimumab (PD-1/CTLA-4) hits 78% 6-mo rPFS in metastatic NEPC/AVPC
CHAMP (NCT04709276) is a multicenter, single-arm Phase 2 trial testing cabazitaxel (taxane microtubule inhibitor) + carboplatin (platinum) with dual checkpoint blockade nivolumab (PD-1) and ipilimumab (CTLA-4),…
NCT04709276 - Trial result
Prostate cancer
Enzalutamide + PARP inhibitor rucaparib adds PSA drops—but no clear rPFS/OS win in all-comer 1L mCRPC (CASPAR)
Alliance A031902 (CASPAR; NCT04455750) tested enzalutamide (androgen receptor inhibitor) plus rucaparib (PARP inhibitor) vs enzalutamide + placebo as first-line therapy for metastatic castration-resistant prostate…
NCT04455750 - Trial result
Prostate cancer
Fuzuloparib (PARP inhibitor) + abiraterone extends rPFS in 1L mCRPC, with biggest lift in DRD+
FUZUPRO (NCT04691804) is an international, randomized, double-blind Phase 3 trial testing fuzuloparib (oral PARP inhibitor) 150mg BID plus abiraterone acetate/prednisone (AA-P) vs placebo + AA-P as first-line therapy…
NCT04691804 - Trial result
Prostate cancer
A-DREAM (Alliance A032101): Intermittent ADT+ARPI interruption delivers 41% 18‑mo treatment-free eugonadal recovery in mHSPC
A-DREAM is a single-arm Phase 2 de-escalation strategy testing interruption of testosterone suppression (ADT/TS) plus an androgen receptor pathway inhibitor (ARPI) after an “exceptional response” (PSA<0.2ng/mL on…
- Trial result
Prostate cancer
Darolutamide (AR antagonist) + ADT drives deep PSA suppression across older/comorbid mHSPC subgroups
Darolutamide (DARO), an androgen receptor inhibitor, was evaluated with androgen deprivation therapy (ADT) vs placebo + ADT in the Phase 3 ARANOTE trial (NCT04736199) in metastatic hormone-sensitive prostate cancer…
NCT04736199 - Trial result
Prostate cancer
BAT (Supraphysiologic Testosterone) + Sipuleucel‑T Drives 100% PA2024 ELISPOT Responses in mCRPC
Bipolar androgen therapy (BAT; testosterone cypionate 400mg IM q4w with ongoing ADT) was given for two cycles before sipuleucel‑T (autologous PAP–GM‑CSF–primed cellular immunotherapy) in a Phase II, Simon two‑stage…
NCT06100705 - Trial result
Prostate cancer
YL201 (B7-H3–targeted ADC) posts 33% ORR and 11.8-mo rPFS in heavily pretreated mCRPC (2.4 mg/kg)
YL201 is an anti-B7H3 antibody–drug conjugate (ADC) evaluated as monotherapy in a Phase 2 study in metastatic castration-resistant prostate cancer after ≥1 androgen receptor axis-targeted therapy (ARAT) and ≤2…
NCT06241846 - Trial result
Prostate cancer
CONV01-α (Ac-225 PSMA–mAb alpha-radioconjugate) drives 45% PSA50 in Lu-PSMA–pretreated mCRPC
Ac-225 rosopatamab tetraxetan (CONV01-α) is an actinium-225 alpha-emitting radionuclide conjugated to a PSMA-targeting monoclonal antibody, evaluated in the Phase 2 CONVERGE-01 Part 3 dose-escalation/initial…
NCT06549465 - Trial result
Prostate cancer
ST-DoxPCa H&E Biomarker Identifies mHSPC Patients Most Likely to Benefit From Docetaxel
ST-DoxPCa is an AI computational pathology biomarker that infers spatial gene-expression patterns from routine H&E to predict docetaxel benefit in metastatic hormone-sensitive prostate cancer, using a Vision…
NCT00309985 - New trial
Prostate cancer
Phase 2 ADT + ARPI androgen-receptor signaling inhibition with risk-adapted de-escalation in mHSPC
Georgetown University and the MedStar Health network are running this prospective, interventional, non-randomized Phase 2 pragmatic study (up to 108 patients) to test whether a risk-adapted intensification strategy…
NCT07645326 Exploratory - New trial
Prostate cancer
Phase 2 MR-guided SBRT uses MR-Linac image guidance (no drug; radiation dose de-escalation).
This Memorial Sloan Kettering Cancer Center–sponsored Phase 2 randomized trial (DESTINATION 2) tests whether *intra-prostatic dose de-escalation* can reduce urinary/bowel side effects while preserving tumor control…
NCT07635238 Exploratory - New trial
Prostate cancer
Phase 2 sacituzumab tirumotecan TROP2-directed ADC (topoisomerase I payload) in post-platinum NEPC.
This Phase 2, open-label, single-arm study tests sacituzumab tirumotecan (a TROP2-targeting monoclonal antibody–drug conjugate carrying a belotecan-derived topoisomerase I inhibitor payload) in metastatic…
NCT07639086 Exploratory - New trial
Prostate cancer
Phase 2 61Cu-NU101 PSMA-targeted PET radiotracer (PSMA ligand) vs Pylarify in prostate cancer
This Phase 2, two-center, single-arm diagnostic comparison study tests whether the investigational PET radiotracer 61Cu-noDAGa-PSMA I&T (61Cu-NU101) can match or outperform the current standard 18F-piflufolastat…
NCT07635524 Exploratory - New trial
Prostate cancer
Phase 2 Microboost SBRT focal SIB (DNA damage via ionizing radiation) with whole-gland de-escalation
Georgetown University’s Phase 2 MIDAS trial tests whether MRI-defined “microboost” SBRT can safely intensify dose to up to 4 intraprostatic lesions (45 Gy in 5 fractions) while de-escalating dose to the remainder of…
NCT07644598 Exploratory - New trial
Prostate cancer
Phase 1/2 GDC-1261 trial in prostate cancer; no disclosed MOA/target.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07567846 First-in-human - New trial Spotlight
Prostate cancer
Phase 3 AZD2265 (FPI-2265) Actinium-225 PSMA-targeted alpha radioconjugate vs physician’s-choice SOC in mCRPC
AstraZeneca’s VECTRA-01 is a randomized, multicenter Phase 3 study testing AZD2265 (FPI-2265), a PSMA-binding small-molecule radioconjugate labeled with actinium-225 that delivers high–linear energy transfer alpha…
NCT07611110 Registrational - New trial
Prostate cancer
Phase 1 FLT (thymidine analog PET tracer) vs CSE-MRI (water–fat chemical shift) for active marrow mapping
University of Wisconsin–Madison is running this small, paired-imaging study in men with metastatic PSMA-positive castration-resistant prostate cancer who are already scheduled for 177Lu-PSMA radiopharmaceutical…
NCT07609225 Exploratory - New trial
Prostate cancer
Phase 2 zanzalintinib c-MET/VEGFR tyrosine kinase inhibitor in visceral/soft-tissue mCRPC.
This single-arm Phase 2 study tests zanzalintinib, an oral small-molecule multi-kinase inhibitor targeting c-MET (HGFR) and VEGFR pathways that drive tumor growth, invasion, and angiogenesis. The trial enrolls men…
NCT07608718 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.